Please login to the form below
drug treatment
This page shows the latest drug treatment news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
The drug has been specifically recommended for NHS use alongside Genentech’s Avastin (bevacizumab) as a maintenance treatment in adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, whose ... NICE’s final draft
Latest news
-
Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
The phase 3b DAYLIGHT trial has been evaluating the drug as a treatment option for menopausal patients experiencing moderate-to-severe vasomotor symptoms (VMS) and considered unsuitable for hormone therapy. ... the drug also shown to reduce sleep
-
Levofloxacin revealed as first effective treatment for multi-drug resistant TB
UCL researchers found that levofloxacin prevented MDR-TB by 60%. Two landmark clinical trials involving researchers at University College London (UCL) have demonstrated that levofloxacin is the first effective treatment to ... The MDR-TB preventative
-
Almirall granted EC approval for Ebglyss in moderate-to-severe atopic dermatitis
The regulator has specifically approved the drug as a treatment option for adult and adolescent patients aged 12 years and older with a body weight of at least 40kg and who ... Ebglyss as a monotherapy in adult and adolescent patients with
-
WHO releases 13 interventions to help address antimicrobial resistance
Divided into four pillars, the interventions include: prevention, access to essential health services, timely and accurate diagnosis, and quality-assured treatment. ... diagnosis and treatment of drug-resistant infections.
-
Eli Lilly and Almirall’s lebrikizumab shows sustained improvements in atopic dermatitis
This data also furthers our understanding of the long-lasting benefits of lebrikizumab as a potential first-line biologic treatment for patients.". ... The Committee for Medicinal Products for Human Use has specifically recommended approval for the drug
More from news
Approximately 2 fully matching, plus 1,057 partially matching documents found.
Latest Intelligence
-
The five ‘innovation areas’ driving success in chronic diseases
For example, the recently US Food and Drug Administration (FDA)-approved medication Zavzpret is the first nasal spray-formulated CGRP receptor antagonist for acute treatment of migraine, offering rapid pain relief ... With many countries experiencing a
-
Genomic medicine: collaborating for diverse data
drug effects and identify populations for which a drug would be most effective. ... With genome sequencing, doctors can predict how a patient might respond to a certain drug and adjust that patient’s treatment plan accordingly.
-
Cardiovascular disease: the impact of COVID-19 on patient outcomes
PME: How has research into drug treatments for CVD improved in the last decade? ... JF: CVD drug treatment research has evolved from ‘treating a number’, such as a quantitative amount of blood pressure lowering or LDL-C lowering, to also including an
-
To support patient-centricity in clinical trials, look to rare disease communities
How patients are seeking new treatment options that will advance the care of their communities. ... Instead, patients are actively rolling up their sleeves and partnering with drug companies to seek out new treatment options that will advance the care of
-
Tuberculosis – why it remains a major global public health challenge
high pill burdens, and require 18-24 months of treatment, including daily injections for 6-8 months; however, globally, few patients with drug-resistant TB have received these new treatments to ... for obtaining drug susceptibility testing results before
More from intelligence
Approximately 0 fully matching, plus 56 partially matching documents found.
Latest appointments
-
Finland's Faron Pharmaceuticals appoints new medical director
In his new role he will join Turku-based Faron's executive management team and oversee its drug development strategy, including its clinical programmes for Traumakine and Clevegen. ... Our lead drug candidate Traumakine, for the treatment of Acute
-
Canbex hires former Lilly medical director
As chief medical officer at Canbex Dr Lledó will lead preparations for proof of concept trials for the company's lead candidate VSN16R, an oral drug intended for the treatment of ... As a practicing neurologist and experienced drug developer, I am very
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Advertise to healthcare professionals with Springer Nature
Work with our editorial team to publish a clinical custom article on Springer Nature, building awareness of a disease, treatment breakthrough, or an approved branded drug or medical device.
-
How the WHO hepatitis strategy measures up in the field
There is hope among researchers and drug developers that hepatitis C treatment innovations can be leveraged to find a cure for hepatitis B. ... Despite the availability of treatment options to manage hepatitis B and cure hepatitis C, people across the
-
What does the future hold for clinical trial recruitment?
Drug trials are often competing with each other as pharmaceutical rivals race to be the first to develop a drug or treatment. ... treatment and one they would wish to be aware of so they have the chance to participate.
-
Onyx Health Joins Forces with Rare Disease Specialists Actigen
The current focus of Actigen's work is on the development of a drug for a potential breakthrough treatment for the life-limiting rare disease known as MPS II or Hunter ... There are 6, 000 rare diseases affecting approximately 300 million people worldwide
-
Improving healthcare for rare disease patients
There is only a very small target market, meaning that the company developing the treatment would find it difficult to cover the development costs of a new drug, while also keeping ... In February this year, it was announced that the world’s most
More from PMHub
Approximately 0 fully matching, plus 16 partially matching documents found.
Subscribe to our email news alerts
- OPEN Health and Nested Knowledge announce strategic research collaboration to leverage AI technologies for evidence synthesis
- FDA approves two cell-based gene therapies for sickle cell disease
- Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma
- New economic data reveals risk of disincentivising UK life sciences growth
- WHO countries hold seventh INB meeting to prevent global pandemics
- The start of a beautiful friendship
No results were found
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Virtual care – negotiating barriers to adoption offers glimpses of an exciting future
- Digital tools and innovative healthcare promise to address pressing healthcare issues if they can satisfy concerns over access, security and affordability...
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
